FI952961A0 - Dolostatiinianalogeja - Google Patents

Dolostatiinianalogeja

Info

Publication number
FI952961A0
FI952961A0 FI952961A FI952961A FI952961A0 FI 952961 A0 FI952961 A0 FI 952961A0 FI 952961 A FI952961 A FI 952961A FI 952961 A FI952961 A FI 952961A FI 952961 A0 FI952961 A0 FI 952961A0
Authority
FI
Finland
Prior art keywords
dolostatiinianalogeja
novel
chdcheco
formula
preparation
Prior art date
Application number
FI952961A
Other languages
English (en)
Swedish (sv)
Other versions
FI952961A (fi
Inventor
Andreas Haupt
Bernd Janssen
Kurt Ritter
Dagmar Klinge
Gerhard Keilhauer
Cynthia Romerdahl
Teresa Barlozzari
Xiao-Dong Qian
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of FI952961A publication Critical patent/FI952961A/fi
Publication of FI952961A0 publication Critical patent/FI952961A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Window Of Vehicle (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI952961A 1992-12-16 1995-06-15 Dolostatiinianalogeja FI952961A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99130992A 1992-12-16 1992-12-16
PCT/EP1993/003410 WO1994013695A1 (en) 1992-12-16 1993-12-04 Dolostatin analog

Publications (2)

Publication Number Publication Date
FI952961A FI952961A (fi) 1995-06-15
FI952961A0 true FI952961A0 (fi) 1995-06-15

Family

ID=25537082

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952961A FI952961A0 (fi) 1992-12-16 1995-06-15 Dolostatiinianalogeja

Country Status (24)

Country Link
US (1) US5502032A (fi)
EP (1) EP0674652B1 (fi)
JP (1) JPH08504415A (fi)
CN (1) CN1057095C (fi)
AT (1) ATE196296T1 (fi)
AU (1) AU679479B2 (fi)
BR (1) BR1100019A (fi)
CA (1) CA2151953A1 (fi)
CZ (1) CZ286752B6 (fi)
DE (1) DE69329425T2 (fi)
ES (1) ES2151921T3 (fi)
FI (1) FI952961A0 (fi)
HR (1) HRP931504B1 (fi)
HU (1) HUT72067A (fi)
IL (1) IL107987A (fi)
NO (1) NO952366L (fi)
NZ (1) NZ258882A (fi)
PL (1) PL178766B1 (fi)
RU (1) RU2132334C1 (fi)
SG (1) SG67935A1 (fi)
SI (1) SI9300661A (fi)
TW (1) TW400335B (fi)
WO (1) WO1994013695A1 (fi)
ZA (1) ZA939389B (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
EP1446110A2 (en) * 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2524511A1 (en) * 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
US20060135483A1 (en) * 2004-07-09 2006-06-22 Cheruvallath Zacharia S Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2007008603A1 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
MX2016008444A (es) 2013-12-27 2017-01-11 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de farmacos.
JP6615115B2 (ja) 2013-12-27 2019-12-04 ザイムワークス インコーポレイティド Ｖａｒ２ｃｓａ−薬物コンジュゲート
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
ATE94395T1 (de) * 1986-05-09 1993-10-15 Pulverer Gerhard Verwendung von spezifischen monosacchariden zur herstellung eines arzneimittels zur verhinderung von metastasen maligner tumore.
JP2714402B2 (ja) * 1988-07-13 1998-02-16 日清製粉株式会社 癌転移抑制剤
EP0357332A3 (en) * 1988-08-24 1991-07-31 Merck & Co. Inc. Renin inhibitors useful for the treatment of aids by inhibition of hiv protease
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5138036A (en) * 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
ATE190983T1 (de) * 1991-08-09 2000-04-15 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate

Also Published As

Publication number Publication date
PL309353A1 (en) 1995-10-02
JPH08504415A (ja) 1996-05-14
ZA939389B (en) 1995-06-15
HUT72067A (en) 1996-03-28
NO952366D0 (no) 1995-06-15
HRP931504A2 (en) 1997-02-28
CN1057095C (zh) 2000-10-04
HRP931504B1 (en) 2001-04-30
FI952961A (fi) 1995-06-15
RU95115135A (ru) 1997-06-10
AU5695994A (en) 1994-07-04
CZ286752B6 (en) 2000-06-14
SG67935A1 (en) 1999-10-19
AU679479B2 (en) 1997-07-03
RU2132334C1 (ru) 1999-06-27
CZ157595A3 (en) 1996-01-17
PL178766B1 (pl) 2000-06-30
CA2151953A1 (en) 1994-06-23
WO1994013695A1 (en) 1994-06-23
HU9501754D0 (en) 1995-08-28
SI9300661A (en) 1994-06-30
BR1100019A (pt) 2000-07-25
IL107987A (en) 1999-10-28
TW400335B (en) 2000-08-01
EP0674652A1 (en) 1995-10-04
IL107987A0 (en) 1994-04-12
ES2151921T3 (es) 2001-01-16
CN1095724A (zh) 1994-11-30
EP0674652B1 (en) 2000-09-13
NO952366L (no) 1995-06-15
US5502032A (en) 1996-03-26
NZ258882A (en) 1997-06-24
DE69329425D1 (de) 2000-10-19
ATE196296T1 (de) 2000-09-15
DE69329425T2 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
FI952961A (fi) Dolostatiinianalogeja
MY124487A (en) Dolastatin derivatives, their preparation and use
DK0642530T3 (da) Dolastatinderivater
DE69128473D1 (de) An sigma-bindungsstellen wirkende stoffe
ES2104682T3 (es) Fluor-compuestos.
MX9203100A (es) Nuevos peptidos, su preparacion y su aplicacion.
ES2120037T3 (es) 1-fenil- o 1-piridinil-benzotriazoles substituidos herbicidas.
TR199701298T1 (xx) Tetralinler.
ES2098338T3 (es) Heteroarilmetilbencenos.
MY114327A (en) Novel peptides, the preparation and use thereof
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.